TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Sunday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD opened at $1.54 on Friday. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $3.07. The company’s fifty day moving average is $1.67 and its two-hundred day moving average is $1.80.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.